

Cancer diagnostics based on novel biomarkers for breast and colorectal malignancies

By *abchain*
Created 2014-01-30 10:30



[Previous page](#) ↩

[1]

Country:	Region:
Israel	Middle East
Logo	Organisation name:

Title:



Cancer diagnostics based on novel biomarkers for breast and colorectal malignancies

Keywords:

Description:

An Israeli SME is a cancer diagnostics company focused on breast and colorectal cancer developing a pipeline of proprietary products for screening and diagnosis of cancer. The assay is based on novel blood cancer biomarkers and will integrate the company's proprietary biomarkers with other relevant markers or technology platform to detect colorectal cancer and advanced Adenoma stage. Looking for collaboration by joint venture or research cooperation for a new tumor marker or new technology.

The Israeli company develops multi biomarker panels for early diagnosis, monitoring therapy and companion diagnostics of Colorectal and breast cancers. They develop molecular blood test and biopsy assays for In-vitro diagnostics use.

The Problem

- Colorectal cancer is a major unmet need: 50,000 deaths in U.S. a year
- Colon Cancer Epidemic: 150,000 new cases in U.S. and 600,000 deaths world-wide.
- Over 80 million Americans are eligible for screening. This number will grow to 100 million by 2020
- Screening for colorectal cancer (CRC) has shown to reduce cancer-related mortality, however, acceptance and compliance to current programs are poor and most physicians are not happy with the Fecal Occult blood test (FOBT)

The Solution

- Developing new, more acceptable non-invasive tests for the detection of cancerous and precancerous colorectal lesions would not only allow pre-selection of individuals for colonoscopy, but may also prevent cancer by removal of precancerous lesions.
- The proposed product is a panel of molecular biomarkers detected by reverse transcription-PCR (RT-PCR), or real-time quantitative-PCR (Q-PCR). The company is looking for new colorectal cancer biomarkers or platform technology to expand its panel.
- The biomarker panel will consists of 5-10 RNA markers. Preliminary results showed high expression of several biomarkers in pre-cancer stage (Non-adenomatous and Adenoamatous) as well as early stage carcinoma.

Further Development

Following development and initial validation, this proposed product should be further confirmed in a large clinical study to be able to demonstrate that screening for colorectal pre-cancerous state with a blood-based test may be as feasible as screening for invasive cancer.

The purpose of this request is to join forces for the development of a new product. The cooperation can be

with partners from companies, R&D institutes or academia.

Stage of development:

Under development/lab tested

Key Benefits:

- Novel and innovative biomarkers
- High sensitivity and specificity compared to current diagnostic tools
- Detection for both early (currently are 60% are detected in late stage) and recurring disease as compared to individual markers

Applications:

Patent status:

Patents granted

Commercial Partnering:

- Type of partner sought:
Industry: Pharmaceutical or Diagnostics company
Academic institutes and research organizations
 - Specific area of activity of the partner:
Company or research entity active in the field of solid cancer biomarker research, drug development, or clinical validations
 - Task to be performed:
Joint Venture – co-development and clinical studies for colorectal cancer biomarker panel
- Joint venture agreement
Research cooperation agreement

Document (NCD) download:

Contact:

Contact person: Nils Haarman
E-mail: nils.haarman@agentschap.nl 
Phone number: +31 (0)88 - 6025843 :

[Previous page](#) 

[1]

Source URL: <http://www.antibodychain.com/node/62066>

Links:

[1] [http://www.antibodychain.com/javascript:history.go\(-1\)](http://www.antibodychain.com/javascript:history.go(-1))